Anavex Life Sciences Corp (AVXL)

[Rubyred77]

NEW YORK, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present a corporate overview at the 18th Annual BIO CEO & Investor Conference.

Dr. Missling’s presentation is scheduled to take place on Tuesday, February 9, 2016 at 1:30 p.m. ET at the Waldorf-Astoria Hotel, Conrad Suite, in New York, NY. Investors may view Dr. Missling’s presentation via live webcast (http://www.veracast.com/webcasts/bio/ceoinvestor2016/85223495157.cfm) or access an archived version via Anavex.com.

The 18th Annual BIO CEO & Investor Conference is hosted by the Biotechnology Industry Organization. It is the largest independent investor conference focused on established and emerging publicly traded and select private biotech companies.